Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol Compared to Iron Sucrose Trial (FIRST) in Chronic Kidney Disease
2009-015630-30Phase 2Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Mar 2010
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of ferumoxytol in iron deficiency anemia (IDA) and chronic kidney disease (CKD) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoints: Safety and Efficacy (hemoglobin/iron parameters). Started Mar 2010; status: completed.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-015630-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015630-30.